BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:19 PM
 | 
Jan 03, 2008
 |  BC Extra  |  Company News

FDA reviewing ESA data

FDA said it is reviewing data from two Phase III trials in which cancer patients were treated with erythropoiesis-stimulating agents (ESAs) to achieve a hemoglobin (Hb) level of at least 12 g/dL. The agency said the studies -- PREPARE and GOG-191 -- were not among the six studies that...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >